	US 12,083,091 B2
	Inhibitors of glucosylceramide degradation in the treatment of diseases of the motor units
Michael Spedding, Le Vesinet (FR); Alexandre Henriques, Bischheim (FR); and Jean-Philippe Loeffler, Berstett (FR)
Assigned to SPEDDING RESEARCH SOLUTIONS, Le Vesinet (FR); UNIVERSITE DE STRASBOURG, Strasbourg (FR); and INSERM—INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, Paris (FR)
Filed by SPEDDING RESEARCH SOLUTIONS, Le Vesinet (FR); UNIVERSITE DE STRASBOURG, Strasbourg (FR); and INSERM—INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, Paris (FR)
Filed on Sep. 29, 2020, as Appl. No. 17/036,860.
Application 17/036,860 is a continuation of application No. 16/092,749, abandoned, previously published as PCT/EP2017/058705, filed on Apr. 11, 2017.
Claims priority of provisional application 62/320,728, filed on Apr. 11, 2016.
Prior Publication US 2021/0077453 A1, Mar. 18, 2021
Int. Cl. A61K 31/336 (2006.01); A61K 31/137 (2006.01); A61K 31/19 (2006.01); A61K 31/4025 (2006.01); A61K 31/4453 (2006.01); A61P 21/00 (2006.01)

CPC A61K 31/336 (2013.01) [A61K 31/137 (2013.01); A61K 31/19 (2013.01); A61K 31/4025 (2013.01); A61K 31/4453 (2013.01); A61P 21/00 (2018.01)]

3 Claims

1. A method for the treatment of a disease of the motor units, wherein the disease is Amyotrophic Lateral Sclerosis (ALS), and wherein the method comprises administering to a patient in need thereof a pharmaceutical composition consisting of ambroxol and/or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable carrier.